Repair & Recovery Peptides

BPC-157 10mg

£20.00

Lyophilised research peptide · 10mg per vial

BPC-157 is a synthetic 15-amino-acid peptide studied in tendon-cell movement, cellular stress responses and blood-vessel signalling. This product supplies one 10mg lyophilised vial of BPC-157—the standalone material, not a BPC-157/TB-500 blend, refill or pen. 1

For laboratory research only; not for human or veterinary use.

Request batch documentation

UK dispatch from Birmingham · Plain outer packaging · Pre-purchase product and documentation enquiries

Description

What you receive

This listing is for BPC-157 in a sealed vial as lyophilised, or freeze-dried, material. It is not a premixed liquid. The 10mg designation is the labelled amount per vial, not a liquid volume or solution concentration.

Product detail Description
Product BPC-157 10mg
Supplied presentation One lyophilised vial
Labelled quantity 10mg per vial
Named peptide BPC-157; also written BPC157 or BPC 157
Peptide class Synthetic pentadecapeptide: 15 amino-acid residues 1
Reference sequence GEPPPGKPADDAGLV 4
Parent-reference molecular formula C₆₂H₉₈N₁₆O₂₂ 7
Parent-reference molecular weight 1419.5 g/mol 7

The sequence, formula and molecular weight identify the reference peptide. The supplied chemical form and any lot-specific analytical results must be matched to the applicable product documentation; database values are not measurements of the vial.

Which BPC-157 product should I choose?

Choose the 10mg vial when your procurement requirement is BPC-157 alone in lyophilised-vial form. The related products below are different catalogue items, not alternative names for this product.

Catalogue item Labelled composition Presentation distinction
BPC-157 10mg — this product 10mg BPC-157 Standalone lyophilised vial
BPC-157 Refill 10mg 10mg BPC-157 Separate refill-cartridge listing
BPC-157 10mg Pen 10mg BPC-157 Separate pen-format listing
BPC-157 / TB-500 Blend 10mg 5mg BPC-157 + 5mg TB-500 Two named materials co-lyophilised in one vial

The standalone vial and the 10mg blend do not contain the same labelled amount of BPC-157. The blend’s 10mg refers to its combined contents. A single-material preparation and a blend also answer different experimental questions: adding a second peptide introduces another variable.

For the broader presentation differences, read research-peptide vials versus pen formats. Check the specific refill or pen record for its supplied components and compatibility; this vial does not establish those attributes.

Batch documentation before you buy

You can enquire about the available documentation before placing an order. Use Batch Documentation or email info@core-research.net, stating “BPC-157 10mg, lyophilised vial” and the information your laboratory requires. You do not need an existing order or container lot number to make a pre-purchase enquiry.

Ask which lot and presentation the report covers, and whether it relates to the material proposed for supply. After delivery, use the container’s lot identifier and your order reference to match the documentation. Core Research’s delivery policy states that, where a certificate exists for the supplied lot, it is issued with the consignment.

When reading the report, distinguish identity—what material was tested—from chromatographic purity and quantitative content. An HPLC peak-area percentage does not, by itself, establish the number of milligrams in a vial. Look for the named sample, method, result, issuer and lot reference. The guide to reading a peptide CoA explains the fields; the HPLC and mass-spectrometry guides cover the methods.

What is BPC-157?

BPC-157 is a synthetic peptide containing 15 amino-acid residues. Its name refers to Body Protection Compound, and the literature relates its sequence to a compound identified in gastric juice. That history describes the research background; it does not mean the commercial material is extracted from gastric juice. 1

Researchers have investigated BPC-157 in tendon-derived cells, vascular cells, isolated tissues and animal models. The studies below focus on cell movement, survival under stress, responsiveness to growth signals, vessel formation and vascular tone. These are related biological processes, but they are not interchangeable measures of tissue repair.

BPC-157 research: mechanisms and findings

Tendon-cell movement and survival: FAK and paxillin

Fibroblasts are connective-tissue cells. In a 2011 study, Chang and colleagues examined rat tendon explants and fibroblasts derived from the Achilles tendon. BPC-157 increased cell outgrowth from the explants, migration and spreading in culture, and survival during hydrogen-peroxide stress. It did not directly increase cell proliferation in the assay reported. 1

The researchers also measured increased phosphorylation of FAK and paxillin, proteins involved in cell-attachment signalling, without an increase in their total protein amounts. Phosphorylation changes a protein’s signalling state. Together, the observations support investigating attachment, movement and stress survival—not simply describing every response as increased cell growth. 1

Growth-hormone responsiveness: receptor expression and JAK2

A later study in rat tendon fibroblasts found that BPC-157 increased growth-hormone receptor expression at both RNA and protein levels. When growth hormone was subsequently added, the pretreated cells showed increased proliferation-related measurements and activation of JAK2, a signalling protein downstream of the receptor. 2

The added growth hormone is an essential condition of that result. It helps explain why this finding differs from the earlier experiment in which BPC-157 alone did not directly increase proliferation. The study concerns altered cellular responsiveness; it does not show that BPC-157 is growth hormone or establish direct binding to the growth-hormone receptor. 2

Angiogenesis: VEGFR2, Akt and eNOS

Angiogenesis is the formation of new blood vessels. Hsieh and colleagues investigated BPC-157 using endothelial-cell experiments, a chick membrane assay and a rat hindlimb-ischemia model. They reported increased vessel-related endpoints and improved blood-flow recovery in the animal model. 3

In cultured human endothelial cells, BPC-157 increased VEGFR2 receptor expression without a corresponding increase in VEGF-A. The study also found receptor internalisation and activation of the VEGFR2–Akt–eNOS pathway; an inhibitor of internalisation reduced associated responses. These findings connect receptor handling with vascular signalling. They do not, by themselves, identify a direct molecular binding target. Human-derived cell cultures are also distinct from clinical trials in people. 3

Vascular tone: nitric oxide and the endothelial lining

A separate study investigated the tension of existing blood vessels rather than new-vessel formation. In isolated rat aortic rings, BPC-157 produced concentration-dependent relaxation that was reduced by removing the endothelial lining or interfering with nitric-oxide signalling. 4

The work linked the response to Src, caveolin-1 and eNOS, and found no direct relaxation effect in its three-dimensional vascular-smooth-muscle model. The endothelial context therefore matters. Vessel relaxation and angiogenesis are different endpoints, even when both involve vascular signalling. 4

Why the experimental model matters

Not every model has produced the same result. Brcic and colleagues reported no direct angiogenic effect in the cell cultures they examined, alongside angiogenesis-related changes during muscle and tendon healing in animals. Later endothelial-cell studies used different experimental systems. 3,5

These differences make the model, comparator and measured endpoint important when interpreting the literature. They also mean that a positive finding in one system should not become a general promise of tissue healing. The BPC-157 research overview provides further context, while the repair-research comparison distinguishes BPC-157 from other catalogue materials.

What does the human evidence show?

Early human reports exist, but their findings need to be read in the context of their design.

A 2021 retrospective knee-pain report followed up 16 people by telephone: 12 had received BPC-157 alone and four had received it with material described as TB4. Most reported improvement, but there was no randomised control group, follow-up varied, and the study did not use specific tools to assess functional improvement. It cannot establish that BPC-157 repaired tissue or that a combination was superior. 8

A 2025 pilot reported short-term observations in two people, both previously exposed to BPC-157. No side effects or measurable changes in the selected biomarkers were reported. That small observation cannot establish long-term safety, uncommon adverse effects or clinical efficacy. 6

These are selected research findings, not a treatment recommendation. Neither the mechanistic studies nor these early human reports demonstrates therapeutic performance or suitability for administration of the supplied research vial.

Storage and laboratory handling

Follow the storage conditions on the supplied label and the documentation applicable to the actual vial. Confirm the required temperature and shelf life before purchase when your laboratory needs a defined storage specification. Do not substitute a generic internet storage period for the supplier’s product-specific information.

Unopened lyophilised material and a prepared solution have different stability requirements. Solvent, pH, concentration, container and exposure history all affect the question being assessed; a period stated for dry material should not automatically be applied after preparation.

Use the BPC-157 solvent and handling guide and peptide storage guide alongside the material specification and your laboratory’s procedure. This page does not prescribe a human-use preparation or administration protocol.

On arrival, check the product name, labelled amount, lot identifier, vial closure and packaging against your order. Retain the documents with the lot record. The receiving checklist provides a structured way to record those checks.

Ordering questions

Where is BPC-157 dispatched from?

Core Research dispatches orders from Birmingham, United Kingdom, using plain outer packaging that does not describe the contents. Where tracking is provided, the details are included in the dispatch email.

How much does delivery cost, and when will it arrive?

Delivery arrangements depend on the destination and order. For the applicable charge and estimated timing, check Shipping & Delivery or contact us with your postcode and required quantity before ordering. Processing and carrier transit are separate, and the published policy does not make a universal next-day delivery promise.

How do I order or request an institutional quotation?

Select the quantity of vials and use Add to basket. Complete payment using the options offered at checkout for your order.

For a university, institute or commercial laboratory, Institutional Procurement provides a quotation and purchase-order-reference enquiry route. Include the institution, delivery address, product and quantity. Raise any need for a particular lot before ordering rather than assuming availability or reservation.

Does 10mg tell me the solution concentration or number of experiments?

No. It is the labelled amount per vial. A solution concentration also requires a defined volume and an appropriate material-content basis; the number of experiments depends on your laboratory’s validated method and its requirements. The product label is not a dose or experimental protocol.

What should I do if the vial is damaged or does not match my order?

Contact info@core-research.net promptly with your order number, the product and lot identifiers, and clear photographs of the parcel, label and any visible issue. Keep the packaging and raise the discrepancy before using the material. For a delayed or unexpectedly warm shipment, retain the tracking details and follow the arrival-condition guide.

Order BPC-157 10mg

Select the standalone 10mg lyophilised vial using the purchase panel. For a specification or documentation question, contact Core Research before ordering.

Add to basket · Ask about this product · Request batch documentation

Research references

[1] Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774–780. DOI: 10.1152/japplphysiol.00945.2010.

[2] Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. DOI: 10.3390/molecules191119066.

[3] Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323–333. DOI: 10.1007/s00109-016-1488-y.

[4] Hsieh MJ et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports. 2020;10:17078. DOI: 10.1038/s41598-020-74022-y.

[5] Brcic L et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology. 2009. PMID: 20388964.

[6] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025;31(5):20–24. PMID: 40131143.

[7] NCBI PubChem. BPC-157, CID 9941957. Reference identity record. Formula and molecular-weight values are reference data, not batch measurements.

[8] Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021. PMID: 34324435.

Additional information

Format

Vial

Strength

10mg